VYGR

Voyager Therapeutics Inc

Add to Watchlist

Advanced Chart

3.470

-0.060(-1.700%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

3.5787

Open

3.510

VWAP

3.46

Vol

175.87K

Mkt Cap

191.94M

Low

3.415

Amount

607.93K

EV/EBITDA(TTM)

Total Shares

54.39M

-74.75M

EV/OCF(TTM)

P/S(TTM)

2.50

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

15.93M

-35.33%

15.79M

-46.61%

13.55M

-30.56%

Estimates Revision

The market is revising Downward the revenue expectations for Voyager Therapeutics, Inc. (VYGR) for FY2025, with the revenue forecasts being adjusted by -3.07% over the past three months. During the same period, the stock price has changed by -38.04%.

Revenue Estimates for FY2025

Revise Downward

-3.07%

In Past 3 Month

Stock Price

Go Down

-38.04%

In Past 3 Month

8 Analyst Rating

323.92% Upside

Wall Street analysts forecast VYGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYGR is 14.71 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

323.92% Upside

Current: 3.470

Low

9.00

Averages

14.71

High

30.00

323.92% Upside

Current: 3.470

Low

9.00

Averages

14.71

High

30.00

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$30

2025-04-08

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$30

2025-04-08

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$30

2025-03-13

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$30

2025-03-13

Reiterates

Strong Buy

Reason

Canaccord Genuity

Sumant Kulkarni

Strong Buy

Maintains

$14 → $12

2025-03-13

Reason

Canaccord Genuity

Sumant Kulkarni

Price Target

$14 → $12

2025-03-13

Maintains

Strong Buy

Reason

Canaccord lowered the firm's price target on Voyager Therapeutics to $12 from $14 and keeps a Buy rating on the shares. The firm said they reported its 4Q24 results showing Operating expenses came in at $44.6M versus estimates of $43.0M, and collaboration revenue was $6.3M versus $10.0M estimate. Canaccord believes the delta in both was most likely driven by the timing of R&D activity, which can be difficult to predict.

Cantor Fitzgerald

Pete Stavropoulos

Buy

Reiterates

n/a

2025-03-12

Reason

Cantor Fitzgerald

Pete Stavropoulos

Price Target

n/a

2025-03-12

Reiterates

Buy

Reason

Wedbush

Yun Zhong

Buy

Reiterates

n/a

2025-03-12

Reason

Wedbush

Yun Zhong

Price Target

n/a

2025-03-12

Reiterates

Buy

Reason

Wells Fargo

Yanan Zhu

Buy

Maintains

$12 → $10

2025-03-12

Reason

Wells Fargo

Yanan Zhu

Price Target

$12 → $10

2025-03-12

Maintains

Buy

Reason

Wells Fargo analyst Yanan Zhu lowered the firm's price target on Voyager Therapeutics (VYGR) to $10 from $12 and keeps an Overweight rating on the shares. The firm highlights 2025 catalysts, including Merck's (MRK) anti-tau Phase 1 data in mid-2025 with read-thrus to VY7523 given similar epitopes, and Voyager's ALPL preclinical data later in 2025, which could inform differentiation vs. TfR brain shuttle.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Voyager Therapeutics Inc (VYGR.O) is -2.03, compared to its 5-year average forward P/E of -3.37. For a more detailed relative valuation and DCF analysis to assess Voyager Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.37

Current PE

-2.03

Overvalued PE

-0.77

Undervalued PE

-5.96

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.47

Current EV/EBITDA

0.88

Overvalued EV/EBITDA

3.24

Undervalued EV/EBITDA

-6.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

10.85

Current PS

2.95

Overvalued PS

24.54

Undervalued PS

-2.84

Financials

Annual

Quarterly

FY2024Q4

YoY :

-93.03%

6.28M

Total Revenue

FY2024Q4

YoY :

-170.84%

-38.30M

Operating Profit

FY2024Q4

YoY :

-161.15%

-34.49M

Net Income after Tax

FY2024Q4

YoY :

-152.68%

-0.59

EPS - Diluted

FY2024Q4

YoY :

-40.10%

-14.68M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

-178.83%

-23.54

FCF Margin - %

FY2024Q4

YoY :

-977.24%

-549.33

Net Margin - %

FY2024Q4

YoY :

-100.00%

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

234.5K

USD

3-6

Months

58.5K

USD

6-9

Months

34.9K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.7M

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

740.0K

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

234.5K

USD

3-6

Months

58.5K

USD

6-9

Months

34.9K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

VYGR News & Events

Events Timeline

2025-03-31 (ET)

2025-03-31

07:16:21

Voyager Therapeutics announces new data from two preclinical programs

2025-03-11 (ET)

2025-03-11

16:11:12

Voyager Therapeutics reports Q4 EPS (59c), consensus (35c)

2025-03-03 (ET)

2025-03-03

07:10:48

Voyager Therapeutics announces data from SAD trial of VY7523

News

9.0

03-31Newsfilter

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

7.0

03-20Globenewswire

Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm

7.0

03-17PRnewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

People Also Watch

Thornburg Income Builder Opportunities Trust

Cass Information Systems Inc

Claros Mortgage Trust Inc

Treace Medical Concepts Inc

6.720

USD

+0.90%

FAQ

What is Voyager Therapeutics Inc (VYGR) stock price today?

The current price of VYGR is 3.47 USD — it has decreased -1.7 % in the last trading day.

VYGR

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

VYGR News & Events

Events Timeline

News

People Also Watch

FAQ

What is Voyager Therapeutics Inc (VYGR) stock price today?

What is Voyager Therapeutics Inc (VYGR)'s business?

What is the price predicton of VYGR Stock?

What is Voyager Therapeutics Inc (VYGR)'s revenue for the last quarter?

What is Voyager Therapeutics Inc (VYGR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Voyager Therapeutics Inc (VYGR)'s fundamentals?

How many employees does Voyager Therapeutics Inc (VYGR). have?

What is Voyager Therapeutics Inc (VYGR) market cap?